Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity

K. G. M. Park, S. D. Heys, J. B. Murray, P. D. Hayes, J. A. Ashby, C. R. Franks, O. Eremin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalCancer Immunology Immunotherapy
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 1992

Keywords

  • Colorectal cancer
  • Cytotoxicity
  • Interleukin-2
  • Natural cytotoxicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity'. Together they form a unique fingerprint.

  • Cite this

    Park, K. G. M., Heys, S. D., Murray, J. B., Hayes, P. D., Ashby, J. A., Franks, C. R., & Eremin, O. (1992). Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity. Cancer Immunology Immunotherapy, 35(1), 53-58. https://doi.org/10.1007/BF01741055